edoc

Considerations for the development of therapeutic monoclonal antibodies

Swann, P. G. and Tolnay, M. and Muthukkumar, S. and Shapiro, M. A. and Rellahan, B. L. and Clouse, K. A.. (2008) Considerations for the development of therapeutic monoclonal antibodies. Current opinion in immunology, Vol. 20, H. 4. pp. 493-499.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6007444

Downloads: Statistics Overview

Abstract

An increasing number of Investigational New Drug (IND) applications for therapeutic monoclonal antibodies (mAbs) have been submitted to US FDA over the past several years. Monoclonal antibodies and related products are under development for a wide range of indications. In addition, the diversity of antibody-related products is increasing including IgG2/IgG4 subclasses and engineered Fc regions to enhance or reduce antibody effector functionality. Recent findings highlight the need to more fully characterize these products and their activity. Advances in product characterization tools, immunogenicity assessments, and other bioanalytical assays can be used to better understand product performance and facilitate development.
Faculties and Departments:03 Faculty of Medicine > Bereich Querschnittsfächer (Klinik) > Pathologie USB > Allgemeine Pathologie (Tolnay)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Querschnittsfächer (Klinik) > Pathologie USB > Allgemeine Pathologie (Tolnay)
UniBasel Contributors:Tolnay, Markus
Item Type:Article, refereed
Article Subtype:Further Journal Contribution
Bibsysno:Link to catalogue
Publisher:Current Biology
ISSN:0952-7915
Note:Publication type according to Uni Basel Research Database: Journal item
Related URLs:
Identification Number:
Last Modified:20 Jun 2014 07:55
Deposited On:20 Jun 2014 07:55

Repository Staff Only: item control page